Forest gains Cerexa’s antibiotic portfolio from the deal, which includes Cerexa’s lead compound ceftaroline acetate. The drug, which is in phase III trials, exhibits bactericidal activity against the most resistant strains of Gram-positive bacteria, including MRSA, according to Forest.
Forest said that the US market for injectable antibiotics is currently estimated to be between $5 billion and $7 billion using branded pricing for all products. The company plans use its hospital-based salesforce to market the products.